IRAK1/4 inhibitor was originally developed for autoimmune and inflammatory diseases [20], and was effective in-vitro and in-vivo in hematological malignancies (MDS, AML, DLBCL) that overactivate the IRAK1 pathway [13, 18], albeit to a lesser extent. This evidence concerns the gene IRAK1 and hematologic disorder.